Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
Pook D, Geynisman DM, Carles J, de Braud F, Joshua AM, Pérez-Gracia JL, Llácer Pérez C, Shin SJ, Fang B, Barve M, Maruzzo M, Bracarda S, Kim M, Kerloeguen Y, Gallo JD, Maund SL, Harris A, Huang KC, Poon V, Sutaria DS, Gurney H. Pook D, et al. Among authors: geynisman dm. Clin Cancer Res. 2023 Sep 1;29(17):3292-3300. doi: 10.1158/1078-0432.CCR-22-2585. Clin Cancer Res. 2023. PMID: 37339186 Clinical Trial.
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Gilligan T, et al. Among authors: geynisman dm. J Natl Compr Canc Netw. 2019 Dec;17(12):1529-1554. doi: 10.6004/jnccn.2019.0058. J Natl Compr Canc Netw. 2019. PMID: 31805523
Biosimilar biologic drugs: a new frontier in medical care.
Geynisman DM, De Velasco G, Sewell KL, Jacobs I. Geynisman DM, et al. Postgrad Med. 2017 May;129(4):460-470. doi: 10.1080/00325481.2017.1311196. Epub 2017 Apr 3. Postgrad Med. 2017. PMID: 28343424 Review.
Reply to M.R. Litzow et al.
Geynisman DM. Geynisman DM. J Clin Oncol. 2013 Oct 10;31(29):3723-4. doi: 10.1200/JCO.2013.51.8431. Epub 2013 Sep 9. J Clin Oncol. 2013. PMID: 24019547 No abstract available.
Using theory and user-centered design in digital health: The development of the mychoice communication tool to prepare patients and improve informed decision making regarding clinical trial participation.
Fleisher L, Bass SB, Shwarz M, Washington A, Nicholson A, Alhajji M, Geynisman DM, Maurer L, Greener J, Kenny C. Fleisher L, et al. Among authors: geynisman dm. Psychooncology. 2020 Jan;29(1):114-122. doi: 10.1002/pon.5254. Epub 2019 Dec 2. Psychooncology. 2020. PMID: 31654442
A review of economic impact of targeted oral anticancer medications.
Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. Shen C, et al. Among authors: geynisman dm. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):45-69. doi: 10.1586/14737167.2014.868310. Epub 2013 Dec 30. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 24378038 Review.
Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4.
Beck TN, Golemis EA, Geynisman DM. Beck TN, et al. Among authors: geynisman dm. Eur Urol. 2016 Sep;70(3):e75-6. doi: 10.1016/j.eururo.2016.02.048. Epub 2016 Mar 3. Eur Urol. 2016. PMID: 26947605 Free PMC article. No abstract available.
133 results